Presentation is loading. Please wait.

Presentation is loading. Please wait.

H.I.G. BioVentures July 29, 2011. H.I.G. Capital – Corporate Overview  H.I.G. is one of the leading private equity firms in the small-cap segment of.

Similar presentations


Presentation on theme: "H.I.G. BioVentures July 29, 2011. H.I.G. Capital – Corporate Overview  H.I.G. is one of the leading private equity firms in the small-cap segment of."— Presentation transcript:

1 H.I.G. BioVentures July 29, 2011

2 H.I.G. Capital – Corporate Overview  H.I.G. is one of the leading private equity firms in the small-cap segment of the market  Founded in 1993; over $9 Billion under management  More than 200 investment professionals  Offices: North America: Miami, Atlanta, Boston, San Francisco, New York, Maryland Europe: London, Paris, Hamburg  H.I.G. Funds: Venture/Growth Investments: H.I.G. BioVentures; H.I.G. Growth Partners Buyout Investments: U.S. LBO, Europe LBO Distressed Investments: Bayside Capital (debt) Public Equities: Brightpoint Capital  “Institutionalized” management structure/processes with strong financial staff/controls, legal/compliance, IT support, and risk management procedures in place  Differentiated, value-added strategy has resulted in superior track record 2

3 H.I.G. BioVentures – Background  Established dedicated life science focus in 2004 : Approximately $350 Million in capital under management $150 Million committed to existing portfolio companies Currently investing out of H.I.G. BioVentures II Experienced team focused exclusively on life science investing  Sectors: biopharmaceuticals, medical devices, diagnostics  H.I.G. BioVentures is the lead or co-lead investor in all investments Active board representation in all companies 7

4 H.I.G. BioVentures – Team  Four senior investment professionals with collectively more than 30 years of venture capital investing experience  The H.I.G. BioVentures team has complementary backgrounds covering Research and intellectual property Product and process development Business development Operations Finance Sales and marketing  The H.I.G. BioVentures team also has a deep network of advisors, co- investors, corporate leaders, and technical consultants to leverage during due diligence and on behalf of portfolio companies 8

5 H.I.G. BioVentures – Industry Leadership  The H.I.G. BioVentures team is active with numerous academic and non-profit organizations Boards of regional venture capital organizations: o Mid-Atlantic Venture Association (MAVA), FL Bio, GA Bio Board and committee participation at national and regional conferences: o Bio-Investor Forum, Mid-Atlantic Bio, Southeast Bio Investor Forum, FL Venture Forum, Midwest Healthcare Investor Network Board/advisory member for universities and entrepreneurial organizations : o Johns Hopkins Alliance, Maryland Technology Enterprise Institute, North Texas Enterprise Corporation, Texas Bioscience Council, Coulter Foundation (Emory, Ga. Tech), Sid Martin Biotechnology Incubator, Univ. Miami, Univ. Florida, Univ. Delaware Research Foundation, Virginia CIT Gap Fund Investment Board (affiliated with all Virginia Universities), Enterprise Florida Not-for-profit boards : o Adventist Healthcare Speaker/panelist : o Multiple national and regional conferences including BIO

6 H.I.G. BioVentures – Aaron Davidson 10  Executive management at Eli Lilly and Company Business development Sales and marketing Finance General management  Venture capital experience at Ventures West Leading Canadian healthcare investor  Operating history at Eli Lilly and Company and venture-backed SYN-X Pharma  Broad network in the pharmaceutical and biotechnology industry as well within the venture capital community.  M.B.A., Harvard Business School  B.Comm., McGill University (305)

7 H.I.G. BioVentures – Bruce Robertson 11  Operating experience in both business development and R&D IGEN (acquired by Roche) W.R. Grace  Venture capital experience at Toucan Capital and GIV Venture Partners  Extensive relationships in the Mid-Atlantic’s financial, entrepreneurial and scientific/academic community  Well-connected within broad venture capital community  M.B.A., Harvard Business School  Ph.D., University of Delaware (Biomedical Engineering)  B.S.E., University of Pennsylvania (305)

8 H.I.G. BioVentures – Michael Wasserman 12  Operating experience in entrepreneurial/venture- backed biotechnology Founder and VP, Business Development at CELLutions Biosystems (acq. by Cedarlane Labs)  Background in early-stage technology transfer and development as a Principal with Innovations Foundation  Clinical drug development and regulatory expertise based on tenure at Advanced Therapeutics  Extensive network and deal flow resources in multiple geographies – Southeast, Midwest, Texas, Ohio, etc.  Ph.D., University of Toronto (Pharmacology)  B.S., McGill University (305)

9 H.I.G. BioVentures – Michael Gutch 13  Venture Capital experience at Lilly Ventures, Eli Lilly and Company  Member of the Corporate Finance & Investment Banking group at Eli Lilly and Company  Post-doctoral research experience at Cold Spring Harbor Labs and UCSF  Strong associations in the pharmaceutical and entrepreneurial communities and networked throughout the Midwest and Northwest  M.B.A., Indiana University  Ph.D., State University of New York (Molecular & Cellular Pathology)  B.S., Alfred University (305)

10 H.I.G. BioVentures – Investment Strategy Areas of Unmet Medical Need Clear and meaningful clinical end-points Short clinical development timelines to demonstrate proof- of-concept in appropriate patient groups Large, attractive markets Significant unmet medical needs Chronic or acute care high value per patient disease indications Scientific and clinical validation well established Differentiation from current standard of care Regulatory precedent established Extensive networks outside of CA and MA resulting in proprietary deal flow Approximately 80% of investments in “secondary geographies” 14 Investment Strategy Validation & Differentiation Broad Source of Deal Flow Efficient Clinical Development

11 H.I.G. BioVentures – Partnering with Industry  H.I.G. BioVentures values its long-term relationships with the pharma and medical device industries  H.I.G. BioVentures has: Co-invested with corporate venture capital groups such as MedImmune Ventures, SROne, Novo A/S Strong relationships with most pharmaceutical and med-tech corporate venture capital and business development groups Ongoing discussions with CVC and BD groups on existing portfolio companies and new deal opportunities  H.I.G. BioVentures portfolio companies have recently completed transactions with: 17

12 H.I.G. BioVentures – Summary  Dedicated to investing in high potential life sciences companies  Team of experienced investment professionals with deep domain knowledge  Proprietary deal flow developed through a broad relationship network  Ability to leverage the more than 200 investment professionals across the H.I.G. Capital platform  Building business relationships with pharmaceutical, biotechnology, and medical device companies 18

13 Questions?


Download ppt "H.I.G. BioVentures July 29, 2011. H.I.G. Capital – Corporate Overview  H.I.G. is one of the leading private equity firms in the small-cap segment of."

Similar presentations


Ads by Google